The Politics Of Avandia: CDER Memos Reveal Frustration With External Pressure
Executive Summary
FDA internal memos released in connection with the agency’s regulatory decision on GlaxoSmithKline PLC’s Avandia reflect Center for Drug Evaluation and Research officials’ frustration with the spotlight under which they have been operating for the past three years to evaluate rosiglitazone’s cardiovascular risks.
You may also be interested in...
PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter
FDA’s Oct. 24 public meeting on the renewal of its drug user fee program demonstrated just how strong a position the agency is in regarding the renewal of the Rx part of the “UFA” legislation – most of the complaints were semantic, quite literally.
PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter
FDA’s Oct. 24 public meeting on the renewal of its drug user fee program demonstrated just how strong a position the agency is in regarding the renewal of the Rx part of the “UFA” legislation – most of the complaints were semantic, quite literally.
FDA Still Most Predictable Part of Drug Development, Despite Bumps, Woodcock Says
Janet Woodcock may take a lot of criticism over problems with FDA’s drug application review and approval process, but she maintains sponsor success at gaining agency approval is better than any other portion of the development process.